Cargando…
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Retraction]
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937392/ https://www.ncbi.nlm.nih.gov/pubmed/33688236 http://dx.doi.org/10.2147/IJNRD.S308249 |
Ejemplares similares
-
Validity of urinary monoamine assay sales under the “spot baseline urinary neurotransmitter testing marketing model”
por: Hinz, Marty, et al.
Publicado: (2011) -
Validity of Urinary Monoamine Assay Sales Under the “Spot Baseline Urinary Neurotransmitter Testing Marketing Model” [Expression of Concern]
Publicado: (2020) -
Urinary Neurotransmitter Testing: Considerations of Spot Baseline Norepinephrine and Epinephrine [Retraction]
Publicado: (2020) -
Urinary neurotransmitter testing: considerations of spot baseline norepinephrine and epinephrine
por: Hinz, Marty, et al.
Publicado: (2011) -
Urinary Neurotransmitter Testing: Considerations of Spot Baseline Norepinephrine and Epinephrine [Expression of Concern]
Publicado: (2020)